sertraline_hydrochloride: profile and news

Sertraline for Prevention of Depression Recurrence in Diabetes ... May 1, 2006
Objective To determine whether maintenance therapy with sertraline hydrochloride prevents recurrence of major depression in patients with diabetes. ... - Archives of General Psychiatry

Pfizer Japan Obtains Approval for ZYVOX, Detrusitol, J Zoloft in ... Apr 24, 2006
J ZOLOFT (sertraline hydrochloride), a selective seretonin reuptke inhibitor developed by Pfizer of the US, is the most prescribed drug for the treatment of ... - Japan Corporate News (press release),

Perrigo Company Reports Third Quarter Fiscal 2006 Financial ... Apr 27, 2006
...for desoximetasone gel, ciclopirox olamine cream, terconazole vaginal suppositories and a tentative approval for sertraline hydrochloride tablets during the ... - PR Newswire (press release),

Other information

Indication
For the treatment of posttraumatic stress disorder, depression, obsessive-compulsive disorder and panic disorder

Pharmacology
Sertraline, an antidepressant drug similar to citalopram, fluoxetine, and paroxetine, is of the selective serotonin reuptake inhibitor (SSRI) type. Sertraline has one active metabolite and is used to treat depression, obsessive-compulsive disorder (OCD), panic disorder, and post-traumatic stress disorder.

Mechanism Of Action
It is believed that sertraline inhibits reuptake of serotonin at the neuronal membrane. SSRIs have less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because of decreased binding to histamine, acetylcholine, and norepinephrine receptors.

Drug Category
Antidepressants; Selective Serotonin Reuptake Inhibitors (SSRIs); ATC:N06AB06

Brand Names/Synonyms
Apo-Sertraline; HSDB 7037; Lustral; Sertralina [Spanish]; Sertraline; Sertraline Hydrochloride; Sertralinum [Latin]; Sultamicillin Tosylate; Zoloft

Dosage Forms
Tablets and Oral solution

Absorption
The effects of food on the bioavailability of the sertraline tablet and oral concentrate were studied in subjects administered a single dose with and without food. For the tablet, AUC was slightly increased when drug was administered with food but the Cmax was 25% greater, while the time to reach peak plasma concentration (Tmax) decreased from 8 hours post-dosing to 5.5 hours. For the oral concentrate, Tmax was slightly prolonged from 5.9 hours to 7.0 hours with food.

Interactions